These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 20041876)

  • 1. Somatic mutations of EGFR, ERBB2, ERBB3 and ERBB4 in juxtamembrane activating domains are rare in non-small cell lung cancers.
    Park SW; Chung NG; Han JY; Eom HS; Yoo NJ; Lee SH
    APMIS; 2010 Jan; 118(1):83-4. PubMed ID: 20041876
    [No Abstract]   [Full Text] [Related]  

  • 2. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
    Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Wang YP; Jo KH; Moon SW; Song SY; Lee JY; Yoo NJ; Lee SH
    Cancer Lett; 2006 Jun; 237(1):89-94. PubMed ID: 16029927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation.
    Blons H; Côté JF; Le Corre D; Riquet M; Fabre-Guilevin E; Laurent-Puig P; Danel C
    Am J Surg Pathol; 2006 Oct; 30(10):1309-15. PubMed ID: 17001163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of p53 and epidermal growth factor receptor gene status between primary tumors and lymph node metastases in non-small cell lung cancers.
    Chang YL; Wu CT; Shih JY; Lee YC
    Ann Surg Oncol; 2011 Feb; 18(2):543-50. PubMed ID: 20811949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.
    Bell DW; Gore I; Okimoto RA; Godin-Heymann N; Sordella R; Mulloy R; Sharma SV; Brannigan BW; Mohapatra G; Settleman J; Haber DA
    Nat Genet; 2005 Dec; 37(12):1315-6. PubMed ID: 16258541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor (EGFR) double-activating somatic mutations in exons 19 and 21 in Japanese non-small cell lung cancer patients.
    Masago K; Fujita S; Kim YH; Ichikawa M; Hatachi Y; Fukuhara A; Nagai H; Irisa K; Mio T; Mishima M
    Cancer Genet Cytogenet; 2009 Dec; 195(2):179-82. PubMed ID: 19963121
    [No Abstract]   [Full Text] [Related]  

  • 8. Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations.
    Yuan S; Yu SL; Chen HY; Hsu YC; Su KY; Chen HW; Chen CY; Yu CJ; Shih JY; Chang YL; Cheng CL; Hsu CP; Hsia JY; Lin CY; Wu G; Liu CH; Wang CD; Yang KC; Chen YW; Lai YL; Hsu CC; Lin TC; Yang TY; Chen KC; Hsu KH; Chen JJ; Chang GC; Li KC; Yang PC
    J Clin Oncol; 2011 Sep; 29(25):3435-42. PubMed ID: 21810691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
    Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
    Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients.
    Murray S; Timotheadou E; Linardou H; Vrettou AV; Kostopoulos I; Skrickova J; Papakostantinou C; Christodoulou C; Pectasides D; Samantas E; Papakostas P; Skarlos DV; Kosmidis P; Fountzilas G
    Lung Cancer; 2006 May; 52(2):225-33. PubMed ID: 16567021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR sequence variations and real-time quantitative polymerase chain reaction analysis of gene dosage in brain metastases of solid tumors.
    Franco-Hernandez C; Martinez-Glez V; Arjona D; de Campos JM; Isla A; Gutierrez M; Vaquero J; Rey JA
    Cancer Genet Cytogenet; 2007 Feb; 173(1):63-7. PubMed ID: 17284372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ErbB3 mRNA expression correlated with specific clinicopathologic features of Japanese lung cancers.
    Kawano O; Sasaki H; Endo K; Suzuki E; Haneda H; Yukiue H; Kobayashi Y; Yano M; Fujii Y
    J Surg Res; 2008 May; 146(1):43-8. PubMed ID: 17631905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic mutations of the ERBB4 kinase domain in human cancers.
    Soung YH; Lee JW; Kim SY; Wang YP; Jo KH; Moon SW; Park WS; Nam SW; Lee JY; Yoo NJ; Lee SH
    Int J Cancer; 2006 Mar; 118(6):1426-9. PubMed ID: 16187281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.
    Marchetti A; Martella C; Felicioni L; Barassi F; Salvatore S; Chella A; Camplese PP; Iarussi T; Mucilli F; Mezzetti A; Cuccurullo F; Sacco R; Buttitta F
    J Clin Oncol; 2005 Feb; 23(4):857-65. PubMed ID: 15681531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
    Willmore-Payne C; Holden JA; Layfield LJ
    Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activating and resistance mutations of the epidermal growth factor receptor (EGFR) gene and non-small cell lung cancer: a clinical reality.
    Taus A; Vollmer I; Arriola E
    Arch Bronconeumol; 2011 Feb; 47(2):103-5. PubMed ID: 20678850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.
    Minami Y; Shimamura T; Shah K; LaFramboise T; Glatt KA; Liniker E; Borgman CL; Haringsma HJ; Feng W; Weir BA; Lowell AM; Lee JC; Wolf J; Shapiro GI; Wong KK; Meyerson M; Thomas RK
    Oncogene; 2007 Jul; 26(34):5023-7. PubMed ID: 17311002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.
    Amann J; Kalyankrishna S; Massion PP; Ohm JE; Girard L; Shigematsu H; Peyton M; Juroske D; Huang Y; Stuart Salmon J; Kim YH; Pollack JR; Yanagisawa K; Gazdar A; Minna JD; Kurie JM; Carbone DP
    Cancer Res; 2005 Jan; 65(1):226-35. PubMed ID: 15665299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of EGFR mutation analysis in non-small cell lung cancer.
    Yamamoto H; Toyooka S; Mitsudomi T
    Lung Cancer; 2009 Mar; 63(3):315-21. PubMed ID: 18760859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.